News Releases

Sep 17, 2019
Applied Therapeutics to Present Preclinical Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
NEW YORK , Sept. 17, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced presentation of data at the
Aug 12, 2019
Applied Therapeutics Reports Second Quarter 2019 Financial Results
NEW YORK , Aug. 12, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing novel drug candidates in indications of high unmet medical need, today reported financial results for the second quarter ended June 30, 2019 .
Jun 21, 2019
Applied Therapeutics Reports First Quarter 2019 Financial Results
-Strengthened Financial Position with Recent Initial Public Offering- - Phase 1/2 Trial AT-007 in Adults with Galactosemia Expected to Start This Month - - Pivotal Phase 2/3 Trial for AT-001 in Diabetic Cardiomyopathy Expected to Start Later This Year - NEW YORK , June 21, 2019 (GLOBE NEWSWIRE) --
Jun 07, 2019
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy in Late Breaking Session at the American Diabetes Association 79th Annual Scientific Sessions
AT-001, a novel, potent and selective aldose reductase inhibitor, is expected to start a pivotal study later this year NEW YORK , June 07, 2019 (GLOBE NEWSWIRE) -- Applied Therapeutics Inc. (Nasdaq:APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates
Displaying 1 - 10 of 13